N-803 and BCG for Bladder Cancer
Study Summary
This trial is testing a new drug, N-803, for people with bladder cancer that has not responded to BCG treatment. Patients will receive the new drug through a urinary catheter weekly for 6 weeks, followed by maintenance treatment every 3 or 6 weeks for up to 3 years.
- Bladder Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
What is the precedent for N-803 and BCG research?
"Right now, there are a 20 active research studies being conducted on N-803 and BCG. Out of those 20, 3 are in Phase 3. However, the majority of clinical trials taking place for N-803 and BCG are being conducted in Ann Arbor, Michigan. In total, there are 508 medical research sites running these sorts of experiments."
Could you tell me how many different facilities are coordinating this research project?
"The primary locations for this clinical trial are UCLA Department of Urology in Los Angeles, California, Moffitt Cancer Center in Tampa, Florida, and Karmanos Cancer Institute in Detroit, New York. There are also 15 other locations participating in this trial."
Are people with the specified medical condition still being recruited for this research project?
"That is accurate. The listing on clinicaltrials.gov currently states that the trial is looking for 200 individuals to participate. The trial was first posted on 6/2/2017 and the most recent update was on 10/26/2022. There will be 15 sites enrolling patients."